Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry

Eur Heart J. 2009 Oct;30(19):2318-26. doi: 10.1093/eurheartj/ehp355. Epub 2009 Aug 31.

Abstract

Aims: To determine 3-year event rates in outpatients with vascular disease enrolled in the REduction of Atherothrombosis for Continued Health (REACH) Registry.

Methods and results: REACH enrolled 67 888 outpatients with atherothrombosis [established coronary artery disease (CAD), cerebrovascular disease, or peripheral arterial disease (PAD)], or with at least three atherothrombotic risk factors, from 44 countries. Among the 55 499 patients at baseline with symptomatic disease, 39 675 were eligible for 3-year follow-up, and 32 247 had data available (81% retention rate). Among the symptomatic patients at 3 years, 92% were taking an antithrombotic agent, 91% an antihypertensive, and 76% were on lipid-lowering therapy. For myocardial infarction (MI)/stroke/vascular death, 1- and 3-year event rates for all patients were 4.2 and 11.0%, respectively. Event rates (MI/stroke/vascular death) were significantly higher for patients with symptomatic disease vs. those with risk factors only at 1 year (4.7 vs. 2.3%, P < 0.001) and at 3 years (12.0 vs. 6.0%, P < 0.001). One and 3-year rates of MI/stroke/vascular death/rehospitalization were 14.4 and 28.4%, respectively, for patients with symptomatic disease. Rehospitalization for a vascular event other than MI/stroke/vascular death was common at 3 years (19.0% overall; 33.6% for PAD; 23.0% for CAD). For patients with symptomatic vascular disease in one vascular bed vs. multiple vascular beds, 3-year event rates for MI/stroke/vascular death/rehospitalization were 25.5 vs. 40.5% (P < 0.001).

Conclusion: Despite contemporary therapy, outpatients with symptomatic atherothrombotic vascular disease experience high rates of recurrent vascular events and rehospitalizations.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Ambulatory Care / standards*
  • Anticoagulants / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Coronary Artery Disease / prevention & control*
  • Diabetes Complications / complications
  • Female
  • Follow-Up Studies
  • Hospitalization / statistics & numerical data
  • Humans
  • Hypertension / complications
  • Hypoglycemic Agents / therapeutic use
  • Male
  • Myocardial Infarction / etiology
  • Obesity / complications
  • Peripheral Vascular Diseases / etiology
  • Registries
  • Risk Factors
  • Secondary Prevention
  • Smoking / adverse effects
  • Stroke / etiology

Substances

  • Anticoagulants
  • Antihypertensive Agents
  • Hypoglycemic Agents